BR112017016345A2 - anticorpos anti-transtiretina - Google Patents

anticorpos anti-transtiretina

Info

Publication number
BR112017016345A2
BR112017016345A2 BR112017016345A BR112017016345A BR112017016345A2 BR 112017016345 A2 BR112017016345 A2 BR 112017016345A2 BR 112017016345 A BR112017016345 A BR 112017016345A BR 112017016345 A BR112017016345 A BR 112017016345A BR 112017016345 A2 BR112017016345 A2 BR 112017016345A2
Authority
BR
Brazil
Prior art keywords
ttr
antibodies
transthyretin
accumulation
amyloidosis
Prior art date
Application number
BR112017016345A
Other languages
English (en)
Inventor
Chakrabartty Avijit
N Higaki Jeffrey
S Nijjar Tarlochan
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of BR112017016345A2 publication Critical patent/BR112017016345A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção provê anticorpos que se ligam especificamente à transtiretina (ttr). os anticorpos podem ser utilizados para tratar ou efetuar profilaxia de doenças ou distúrbios associados ao acúmulo de ttr ou acumulo de depósitos de ttr (por exemplo, amiloidose ttr). os anticorpos também podem ser usados para diagnosticar a amiloidose ttr e inibir ou reduzir a agregação de ttr, entre outras aplicações.
BR112017016345A 2015-01-28 2016-01-28 anticorpos anti-transtiretina BR112017016345A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109004P 2015-01-28 2015-01-28
US201562266555P 2015-12-11 2015-12-11
PCT/IB2016/050416 WO2016120811A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (1)

Publication Number Publication Date
BR112017016345A2 true BR112017016345A2 (pt) 2018-03-27

Family

ID=55300737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016345A BR112017016345A2 (pt) 2015-01-28 2016-01-28 anticorpos anti-transtiretina

Country Status (26)

Country Link
US (1) US20160257737A1 (pt)
EP (1) EP3250593B1 (pt)
JP (1) JP7101927B2 (pt)
KR (1) KR102649788B1 (pt)
CN (1) CN107406500B (pt)
AU (1) AU2016210889C1 (pt)
BR (1) BR112017016345A2 (pt)
CA (1) CA2974993A1 (pt)
CO (1) CO2017008482A2 (pt)
CU (1) CU20170098A7 (pt)
DK (1) DK3250593T3 (pt)
EA (1) EA036014B1 (pt)
ES (1) ES2925716T3 (pt)
HR (1) HRP20220918T1 (pt)
HU (1) HUE059592T2 (pt)
MX (1) MX2017009803A (pt)
MY (1) MY193701A (pt)
PE (1) PE20180218A1 (pt)
PL (1) PL3250593T3 (pt)
PT (1) PT3250593T (pt)
RS (1) RS63513B1 (pt)
SA (1) SA517381981B1 (pt)
SG (2) SG10201906696RA (pt)
SI (1) SI3250593T1 (pt)
TW (2) TWI711631B (pt)
WO (1) WO2016120811A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7357609B2 (ja) 2017-10-06 2023-10-06 ノボ ノルディスク エー／エス 抗トランスサイレチン抗体
SG11202004187UA (en) 2017-11-29 2020-06-29 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
EP3814376A4 (en) * 2018-06-26 2022-07-06 Mor Research Applications Ltd. ANTI-TRANSTHYRETIN ANTIBODIES AND THEIR USES
CN111018976B (zh) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 一种抗人心肌肌钙蛋白i的重组抗体
US20210400932A1 (en) * 2018-11-09 2021-12-30 Neurimmune Ag Patient-derived amyloid xenograft non-human animal model
CA3140208A1 (en) * 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
CN116804186B (zh) * 2023-07-05 2023-12-22 中国兽医药品监察所 一种抗鸡传染性贫血病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE60036082T2 (de) 1999-02-05 2008-06-12 Samsung Electronics Co., Ltd., Suwon Verfahren und vorrichtung zur wiederauffindung von texturbildern
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
WO2004050884A2 (de) 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
PT1820022E (pt) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
MY148472A (en) 2007-03-02 2013-04-30 Boehringer Ingelheim Pharma Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2010195710A (ja) 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies

Also Published As

Publication number Publication date
CA2974993A1 (en) 2016-08-04
TW202110896A (zh) 2021-03-16
US20160257737A1 (en) 2016-09-08
KR20170120608A (ko) 2017-10-31
AU2016210889B2 (en) 2021-10-21
TW201636371A (zh) 2016-10-16
HUE059592T2 (hu) 2022-11-28
SI3250593T1 (sl) 2022-09-30
CN107406500A (zh) 2017-11-28
EP3250593A1 (en) 2017-12-06
AU2016210889C1 (en) 2022-02-10
EA201791710A1 (ru) 2017-12-29
DK3250593T3 (da) 2022-08-22
CN107406500B (zh) 2022-02-25
CO2017008482A2 (es) 2018-01-16
SG11201706126WA (en) 2017-08-30
PL3250593T3 (pl) 2022-09-19
JP7101927B2 (ja) 2022-07-19
HRP20220918T1 (hr) 2022-10-28
CU20170098A7 (es) 2018-03-13
RS63513B1 (sr) 2022-09-30
TWI769570B (zh) 2022-07-01
TWI711631B (zh) 2020-12-01
KR102649788B1 (ko) 2024-03-20
JP2018510617A (ja) 2018-04-19
ES2925716T3 (es) 2022-10-19
WO2016120811A1 (en) 2016-08-04
PE20180218A1 (es) 2018-01-31
AU2016210889A1 (en) 2017-08-10
SG10201906696RA (en) 2019-08-27
EA036014B1 (ru) 2020-09-14
MY193701A (en) 2022-10-25
PT3250593T (pt) 2022-08-31
EP3250593B1 (en) 2022-06-22
SA517381981B1 (ar) 2022-05-17
MX2017009803A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
BR112017016330A2 (pt) anticorpos anti-transtiretina
BR112017016324A2 (pt) anticorpos anti-transtiretina
BR112017016345A2 (pt) anticorpos anti-transtiretina
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
BR112019003976A2 (pt) anticorpos anti-tim-3 e seu uso
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CU20200021A7 (es) Anticuerpos anti-transtiretina
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
WO2018007924A3 (en) Anti-transthyretin antibodies
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
WO2018007923A3 (en) Anti-transthyretin antibodies
BR112018072389A2 (pt) anticorpos que reconhecem tau
WO2018007922A3 (en) Anti-transthyretin antibodies
BR112018072394A2 (pt) anticorpos que reconhecem a tau
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112016020366A2 (pt) anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais
BR112018067602A2 (pt) ambrisentan para uso no tratamento de insuficiência renal aguda
AR113345A1 (es) Anticuerpos anti-transtiretina
MY193688A (en) Anti-transthyretin antibodies
EA202090898A1 (ru) Антитранстиретиновые антитела
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
AR103548A1 (es) Anticuerpos anti-transtiretina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]